Bartlett & CO. Wealth Management LLC Grows Holdings in Zoetis Inc. $ZTS

Key Points

• Bartlett & CO. Wealth Management LLC increased its holdings in Zoetis Inc. by 4.0%, owning 367,390 shares valued at approximately $57.3 million after acquiring an additional 14,128 shares in the second quarter.
• Zoetis reported a net income of $1.76 per share for the last quarter, exceeding analysts' expectations, and its revenue rose 4.2% year over year to $2.46 billion.
• Five research analysts rated Zoetis with a Buy rating and the average price target stands at $200.88, while several firms recently adjusted their ratings and targets for the stock.

Bartlett & CO. Wealth Management LLC grew its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 367,390 shares of the company's stock after purchasing an additional 14,128 shares during the period. Bartlett & CO. Wealth Management LLC owned about 0.08% of Zoetis worth $57,295,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. increased its stake in Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after purchasing an additional 189,287 shares during the period. Polen Capital Management LLC increased its stake in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Northern Trust Corp grew its position in shares of Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock worth $1,071,032,000 after buying an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock worth $847,293,000 after buying an additional 109,791 shares in the last quarter. Finally, Brown Advisory Inc. grew its position in shares of Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock worth $725,866,000 after buying an additional 312,746 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

Shares of ZTS stock opened at $146.12 on Wednesday. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $196.55. The stock's 50-day moving average is $150.16 and its 200 day moving average is $155.45. The company has a market cap of $64.76 billion, a P/E ratio of 25.15, a PEG ratio of 2.30 and a beta of 0.88. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the company earned $1.56 earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ZTS. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Argus reissued a "buy" rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.